Genscript Biotech Reports Strong Momentum across All Business Segments

24 August 2021 | Tuesday | News

Genscript Biotech Reports 2021 Interim Financial Results - Strong Momentum across All Business Segments, particularly in Gene & Cell Therapy CDMO - Continue to accelerate R&D investment to capture Future Growth

Genscript Biotech (HKEX: 1548.HK) (GenScript), a global leading biotech company, today announced its audited financial results for the year ended June 30, 2021.

"In the first half of 2021, the Group maintained a strong momentum across all business segments. Among others, our gene and cell therapy CDMO business scored historic breakthrough," said Dr. Patrick Liu, Rotating CEO of GenScript. "Over the past six months, the COVID-19 pandemic is still raging around the world. All GenScript employees overcame challenges and seized industry opportunities amid the pandemic, contributing the Group's rapid growth. In the next few years, GenScript will accelerate strategic investment in the gene and cell therapy industry supply chain in an effort to meet strong demand from customers on this revolutionary industry. We are confident in our ability to continue to create value for our customers and shareholders and fulfill our mission to make people and nature healthier through biotechnology".


  • Revenue of the Group for the six months ended June 30, 2021 was approximately US$229.6 million, representing an increase of 38.0% as compared with approximately US$166.4 million recorded for the same period of 2020
  • Revenue for Biologics Development Service for the six months ended June 30, 2021 was approximately US$31.5 million, within which Gene & Cell Therapy CDMO revenue was approximately US$7.53 million, representing an increase of 253% as compared with approximately US$2.13 million recorded for the same period of 2020      
  • During the Reporting Period, the Group invested significantly into research and development activities as well as talent recruitment, and both of which are key drivers for a sustainable business growth in  the  long run. For the six months ended June 30, 2021, the Group's research and development expense was approximately US$175.1 million, representing an increase of 51.6% as compared with approximately US$115.5 million for the same period in 2020, in which the total investment in research and development was approximately US$154.5 million on cell therapy for the six months ended June 30, 2021, representing an increase of 52.1% as compared with approximately US$101.6 million for the same period of 2020.


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in